Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

Glenn J. Hanna,Anne ONeill,Vickie Y. Jo,Kristine S. Wong,Patrick H. Lizotte,Donald J. Annino,Laura A. Goguen,Jason I. Kass,Eleni M. Rettig,Rosh K. V. Sethi,Jochen H. Lorch,Jonathan D. Schoenfeld,Danielle N. Margalit,Roy B. Tishler,Peter Everett,Anupam Desai,Cloud P. Paweletz,Ann Marie Egloff,Ravindra Uppaluri,Robert I. Haddad

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

2021

6053Background: Locoregional recurrence (LRR) is a major cause of death for patients (pts) with squamous cell carcinoma of the head and neck (SCCHN). With therapy options limited by prior treatment...

Keywords:

Adjuvant
in patient
Nivolumab
basal cell
Oncology
Medicine
Internal medicine
Cause of death
prior treatment
head and neck

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations